These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 31565873)

  • 21. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
    Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
    Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model.
    Suzuki K; Iwai H; Utsunomiya K; Kono Y; Watabe T; Kobayashi Y; Bui DV; Sawada S; Yun Y; Mitani A; Fukui K; Sakai H; Chu HH; Linh NM; Tanigawa N; Kanda A
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer.
    Zhao S; Zhao Y; Zhao Y; Wang G
    Front Endocrinol (Lausanne); 2023; 14():1320044. PubMed ID: 38313845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.
    Mishra A; Pal L; Mishra SK
    World J Surg; 2007 Sep; 31(9):1737-1742. PubMed ID: 17653791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolomics reveals the implication of acetoacetate and ketogenic diet therapy in radioiodine-refractory differentiated thyroid carcinoma.
    Wang J; Xu Q; Xuan Z; Mao Y; Tang X; Yang K; Song F; Zhu X
    Oncologist; 2024 Sep; 29(9):e1120-e1131. PubMed ID: 38760956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells.
    Zhang GQ; Xi C; Shen CT; Song HJ; Luo QY; Qiu ZL
    Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37260320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of the sodium/iodide symporter by retinoids--a review.
    Schmutzler C
    Exp Clin Endocrinol Diabetes; 2001; 109(1):41-4. PubMed ID: 11573138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer.
    Silaghi H; Lozovanu V; Georgescu CE; Pop C; Nasui BA; Cătoi AF; Silaghi CA
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Imaging and Therapy of Differentiated Thyroid Carcinoma in Adults.
    Mulugeta PG; Chi AW; Anderson TM
    Cancer J; 2024 May-Jun 01; 30(3):194-201. PubMed ID: 38753754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
    Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
    Gosain R; Alexander JS; Gill A; Perez C
    Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
    Kogai T; Sajid-Crockett S; Newmarch LS; Liu YY; Brent GA
    J Endocrinol; 2008 Nov; 199(2):243-52. PubMed ID: 18762555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer.
    Tesselaar MH; Crezee T; Schuurmans I; Gerrits D; Nagarajah J; Boerman OC; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
    J Nucl Med; 2018 May; 59(5):780-786. PubMed ID: 29242405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of sodium iodide symporter in thyroid cancer.
    Lakshmanan A; Scarberry D; Shen DH; Jhiang SM
    Horm Cancer; 2014 Dec; 5(6):363-73. PubMed ID: 25234361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake.
    Fletcher A; Read ML; Thornton CEM; Larner DP; Poole VL; Brookes K; Nieto HR; Alshahrani M; Thompson RJ; Lavery GG; Landa I; Fagin JA; Campbell MJ; Boelaert K; Turnell AS; Smith VE; McCabe CJ
    Cancer Res; 2020 Jan; 80(1):102-115. PubMed ID: 31672844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance.
    Shen H; Zhu R; Liu Y; Hong Y; Ge J; Xuan J; Niu W; Yu X; Qin JJ; Li Q
    Drug Resist Updat; 2024 Jan; 72():101013. PubMed ID: 38041877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells.
    Faria M; Domingues R; Bugalho MJ; Matos P; Silva AL
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34831012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing Radioiodine Incorporation in
    Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
    Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
    [No Abstract]   [Full Text] [Related]  

  • 40. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
    Carvalho DP; Ferreira AC
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.